NCT06924827 (CANN-SWITCH) is a Phase 4 clinical trial of Epidiolex 100 mg/mL Oral Solution in Dravet Syndrome (DS), sponsored by Elizabeth Donner.

Who is sponsoring NCT06924827?

NCT06924827 is sponsored by Elizabeth Donner.

What drugs are being tested in NCT06924827?

Interventions in NCT06924827: Epidiolex 100 mg/mL Oral Solution.

What condition does NCT06924827 study?

NCT06924827 studies Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS).

Is NCT06924827 still recruiting?

NCT06924827 is currently not yet recruiting. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT06924827: CANN-SWITCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of the Transition of Children From 'Artisanal' Cannabidiol to Epidiolex

Not yet recruiting Phase 4 Last updated 13 March 2026

What this trial tests

Phase 4 trial testing Epidiolex 100 mg/mL Oral Solution in Dravet Syndrome (DS) in 25 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
1 June 2028

1 June 2029

Quick facts

Lead sponsor	Elizabeth Donner
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 June 2026
Primary completion	1 June 2028
Estimated completion	1 June 2029
Sites	1 location across Canada

Drugs / interventions tested

Epidiolex 100 mg/mL Oral Solution — full drug profile →

Conditions studied

Dravet Syndrome (DS) — all drugs for Dravet Syndrome (DS) →
Lennox-Gastaut Syndrome (LGS) — all drugs for Lennox-Gastaut Syndrome (LGS) →

Sponsor

Elizabeth Donner

Who can join

Adults 2 to 18, any sex, with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The success rate of transition of children from 'artisanal' CBD to Epidiolex.
Time frame: Baseline (visit 2, Day 1) through visit 4 (Day 15), the two-week transition phase.
Participants successfully transitioned from 'artisanal' CBD to Epidiolex if they complete the transition protocol and continue treatment with Epidiolex at visit 2 following the two-week transition phase of the study. The success rate will be determined as the percentage of participants that complete the two-week transition phase.

Sponsor's own description

The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non pharmaceutical-grade) cannabidiol (CBD) to Epidiolex for treatment of seizures. The main questions it aims to answer are: * How well does a gradual switch from 'artisanal' CBD to Epidiolex work? * Does the same dose of Epidiolex as 'artisanal' CBD work best? * What side-effects or medical problems do participants have when switching from 'artisanal' CBD to Epidiolex? Researchers will examine how successful switching from 'artisanal' CBD to Epidiolex is. Participants will: * Gradually increase their dose of Epidiolex and reduce their dose of 'artisanal' CBD until they are taking just Epidiolex * Visit the clinic five times over 20 weeks for checkups and tests * Keep a diary of their seizures, symptoms and the number of times they use a rescue seizure medication

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Epidiolex 100 mg/mL Oral Solution

Trials testing the same drug.

NCT04721691 — Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). · Phase 1 · completed
NCT04642404 — CBD for Dental Pain · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06924827 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elizabeth Donner
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06924827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing